Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Psoriasis
70%
Moderate-to-severe Psoriasis
68%
Psoriasis Severity
32%
Area Index
31%
Severity Index
31%
Psoriasis Area
30%
Ustekinumab
28%
Psoriatic Arthritis
27%
Ixekizumab
19%
Psoriasis Treatment
18%
Spain
15%
Interleukin-17 (IL-17)
14%
Secukinumab
13%
Psoriasis Disease
13%
Dermatology Life Quality Index
13%
Clinical Trials
12%
Quality of Life
12%
Etanercept
12%
Dermatologist
11%
Atopic Dermatitis
11%
Brodalumab
11%
Generalized Pustular Psoriasis
10%
Risankizumab
10%
Placebo
9%
Skin Diseases
9%
Guselkumab
9%
Clinical Practice
9%
Adalimumab
9%
Biological Treatment
8%
Phase II Trial
8%
Long-term Efficacy
8%
Biosimilar
8%
Europe
8%
Methotrexate
8%
Plaque Psoriasis
7%
Interleukin-23 (IL-23)
7%
Confidence Interval
7%
Long-term Safety
7%
Pooled Analysis
7%
Pustular Psoriasis
7%
Itch
6%
Network Meta-analysis
6%
Health-related Quality of Life
5%
Biological Agents
5%
Phase III Clinical Trial
5%
Immune-mediated Inflammatory Diseases
5%
Hidradenitis Suppurativa
5%
Systemic Treatment
5%
Biologic Therapy
5%
Comorbidity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Psoriasis Vulgaris
39%
Ustekinumab
27%
Biological Product
18%
Psoriatic Arthritis
18%
Diseases
16%
Ixekizumab
14%
Clinical Trial
13%
Secukinumab
12%
Etanercept
11%
Brodalumab
11%
Interleukin 17
10%
Placebo
10%
Adverse Event
10%
Atopic Dermatitis
9%
Methotrexate
8%
Risankizumab
8%
Adalimumab
7%
Guselkumab
6%
Pustular Psoriasis
6%
Inflammatory Disease
6%
Biosimilar Agent
5%
Cytokine
5%
Infliximab
5%
Medicine and Dentistry
Psoriasis
73%
Psoriasis Vulgaris
26%
Psoriasis Area and Severity Index
17%
Quality of Life
16%
Diseases
16%
Biological Product
15%
Psoriatic Arthritis
12%
Ustekinumab
11%
Clinical Trial
11%
Generalized Pustular Psoriasis
11%
Dermatology Life Quality Index
11%
Ixekizumab
10%
Dermatology
10%
Etanercept
9%
Biosimilar
9%
Atopic Dermatitis
9%
Inflammatory Disorder
7%
Interleukin 17
7%
Adverse Event
6%
Comorbidity
6%
Adalimumab
6%
Pruritus
6%
Skin Disease
6%
Systemic Therapy
5%
Dermatosis
5%
Prevalence
5%
Cross Sectional Study
5%
Placebo
5%